Atossa Therapeutics
ATOS
14 hedge funds and large institutions have $446K invested in Atossa Therapeutics in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
12% more capital inflows, than outflows
Capital inflows: $51.9K | Capital outflows: $46.2K
0.02% less ownership
Funds ownership: 4.04% → 4.02% (-0.02%)
13% less funds holding
Funds holding: 16 → 14 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$23.5K |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
+$13K |
| 3 |
Goldman Sachs
New York
|
+$12.2K |
| 4 |
GBBWRPM
Genovese Burford & Brothers Wealth & Retirement Plan Management
Sacramento,
California
|
+$1.62K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$1.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock Fund Advisors
San Francisco,
California
|
-$16.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.72K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$9K |
| 4 |
Virtu KCG Holdings
New York
|
-$7.29K |
| 5 |
GA
Geneva Advisors
Chicago,
Illinois
|
-$3K |
ATOS Hedge Fund Activity: Q2 2016 in Review
14 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q2 2016, worth a combined $446K — down 17% from $536K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ATOS and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $23.5K. The largest seller was BlackRock Fund Advisors, cutting an estimated $16.2K.
- 14 institutional investors held Atossa Therapeutics (ATOS) as of Q2 2016, down from 16 in Q1 2016.
- Funds reported $446K of Atossa Therapeutics stock for Q2 2016, down 17% quarter-over-quarter.
- 2 funds opened new Atossa Therapeutics positions in Q2 2016 and 4 closed out, a net change of -2 holders.
- The largest Atossa Therapeutics buyer in Q2 2016 was Renaissance Technologies, an estimated $23.5K added.
- The largest Atossa Therapeutics seller in Q2 2016 was BlackRock Fund Advisors, an estimated $16.2K sold.
Based on aggregated 13F filings for Q2 2016.